177Lu-PSMA-R2 was developed as patent protected equivalent of 177Lu-PSMA-617. This is another prostate-specific membrane antigen (PSMA) based molecule developed as a new prostate cancer therapeutic agent. It is a urea-based PSMA antigen targeting carboxypeptidase-II.
A first clinical trial with this drug was initiated in May 2018, the studies PROter (96 patients, completion 2022), in which the patients are selected on the basis of imaging provided with 68Ga-PSMA-R2.
Leading Emitter: beta electrons (β–)